Seoul National University Hospital is running a clinical trial to test a drug called Tenofovir to treat Burkitt's, asubtype of Non-Hodgkin's Lymphoma. The objective of this study is to analyze factors affecting Hepatitis B Virus (HBV) reactivation in anti-HBc positive patients with Non-Hodgkin's lymphoma treated with rituximab and compare HBV reactivation rates by duration of prophylactic treatment with tenofovir to contribute to the establishment of an effective prevention strategy.
The drug is Tenofovir.
|Study Type :
||Interventional (Clinical Trial)
|Estimated Enrollment :
||None (Open Label)
||A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy
|Actual Study Start Date :
|Estimated Primary Completion Date :
|Estimated Study Completion Date :
For enrollment please visit www.clinicaltrials.gov.